Mukka Proteins Blends Growth With Expansion, Eyes Sri Lanka Entry

Mukka Proteins seems to be balancing performance with ambition. The latest updates show a company that’s not just delivering steady numbers, but also preparing for its next phase of growth.

Numbers Stay On Track

Revenue came in at ₹3.81 billion, with net profit at ₹206.2 million fairly stable performance given the broader cost pressures in the industry. Demand appears consistent, helping the company maintain its footing.

Looking Beyond India

The planned investment in a Sri Lankan entity stands out. It signals Mukka’s intent to build a stronger international presence and tap into new markets, rather than relying only on domestic growth.

Raising Capital For What’s Next

To support these plans, the company has approved raising up to ₹750 million via non-convertible debentures. This gives it the financial room to invest, expand, and manage operations more comfortably.

Key Highlights

• Revenue at ₹3.81 billion for the March quarter
• Net profit reported at ₹206.2 million
• Plans to invest in Sri Lanka-based entity
• Fundraising approved up to ₹750 million via NCDs
• Focus on expansion and strengthening financial base

Sources: Company filings, market disclosures